Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Performance of an AI-powered visualization software platform for precision surgery in breast cancer patients.
Weitz M, Pfeiffer JR, Patel S, Biancalana M, Pekis A, Kannan V, Kaklamanos E, Parker A, Bucksot JE, Romera JR, Alvin R, Zhang Y, Stefka AT, Lopez-Ramos D, Peterson JR, Antony AK, Zamora KW, Woodard S. Weitz M, et al. Among authors: stefka at. NPJ Breast Cancer. 2024 Nov 14;10(1):98. doi: 10.1038/s41523-024-00696-6. NPJ Breast Cancer. 2024. PMID: 39543194 Free PMC article.
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD Jr, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasielec J, Jakubowiak AJ. Derman BA, et al. Among authors: stefka at. JAMA Oncol. 2022 Sep 1;8(9):1278-1286. doi: 10.1001/jamaoncol.2022.2424. JAMA Oncol. 2022. PMID: 35862034 Free PMC article. Clinical Trial.
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
Derman BA, Stefka AT, Jiang K, McIver A, Kubicki T, Jasielec JK, Jakubowiak AJ. Derman BA, et al. Among authors: stefka at. Blood Cancer J. 2021 Feb 5;11(2):19. doi: 10.1038/s41408-021-00418-2. Blood Cancer J. 2021. PMID: 33563912 Free PMC article. Clinical Trial. No abstract available.
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Jasielec JK, et al. Among authors: stefka at. Blood. 2020 Nov 26;136(22):2513-2523. doi: 10.1182/blood.2020007522. Blood. 2020. PMID: 32735641 Free PMC article. Clinical Trial.
The composition of the microbiota modulates allograft rejection.
Lei YM, Chen L, Wang Y, Stefka AT, Molinero LL, Theriault B, Aquino-Michaels K, Sivan AS, Nagler CR, Gajewski TF, Chong AS, Bartman C, Alegre ML. Lei YM, et al. Among authors: stefka at. J Clin Invest. 2016 Jul 1;126(7):2736-44. doi: 10.1172/JCI85295. Epub 2016 Jun 20. J Clin Invest. 2016. PMID: 27322054 Free PMC article.
18 results